NO980420L - Use of griseofulvin to inhibit cancer growth - Google Patents

Use of griseofulvin to inhibit cancer growth

Info

Publication number
NO980420L
NO980420L NO980420A NO980420A NO980420L NO 980420 L NO980420 L NO 980420L NO 980420 A NO980420 A NO 980420A NO 980420 A NO980420 A NO 980420A NO 980420 L NO980420 L NO 980420L
Authority
NO
Norway
Prior art keywords
griseofulvin
cancer growth
inhibit cancer
potentiators
potentiator
Prior art date
Application number
NO980420A
Other languages
Norwegian (no)
Other versions
NO980420D0 (en
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO980420D0 publication Critical patent/NO980420D0/en
Publication of NO980420L publication Critical patent/NO980420L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det omhandles et farmasøytisk preparat for behandling av cancere eller tumorer i pattedyr, som omfatter griseofulvin. Et kjemoterapeutisk middel kan anvendes sammen med griseofulvin, og det kan også potensatorer. Griseofulvin kan også anvendes til å behandle virale infeksjoner, enten alene, sammen med andre virale midler eller sammen med en potensator.A pharmaceutical composition for treating cancers or tumors in mammals comprising griseofulvin is disclosed. A chemotherapeutic agent can be used with griseofulvin, and so can potentiators. Griseofulvin can also be used to treat viral infections, either alone, with other viral agents or with a potentiator.

NO980420A 1995-08-03 1998-01-30 Use of griseofulvin to inhibit cancer growth NO980420L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US183995P 1995-08-03 1995-08-03
US67418196A 1996-07-16 1996-07-16
PCT/US1996/012475 WO1997005870A2 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
NO980420D0 NO980420D0 (en) 1998-01-30
NO980420L true NO980420L (en) 1998-04-03

Family

ID=26669547

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980420A NO980420L (en) 1995-08-03 1998-01-30 Use of griseofulvin to inhibit cancer growth

Country Status (16)

Country Link
EP (1) EP0841914A2 (en)
JP (1) JPH11511136A (en)
KR (1) KR19990036137A (en)
AR (1) AR003176A1 (en)
AU (1) AU713031B2 (en)
BR (1) BR9609920A (en)
CA (1) CA2228503A1 (en)
CZ (1) CZ30598A3 (en)
HU (1) HUP9903506A3 (en)
IL (1) IL123094A0 (en)
MX (1) MX9800945A (en)
NO (1) NO980420L (en)
PL (1) PL324905A1 (en)
SK (1) SK14298A3 (en)
TR (1) TR199800244T2 (en)
WO (1) WO1997005870A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
PT2055313E (en) 1998-11-09 2015-08-25 Biogen Idec Inc Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2003000290A1 (en) * 2001-06-25 2003-01-03 Ajinomoto Co., Inc. Antitumor agents
EP2008652A1 (en) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
EP2204367A1 (en) 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering

Also Published As

Publication number Publication date
JPH11511136A (en) 1999-09-28
IL123094A0 (en) 1998-09-24
CA2228503A1 (en) 1997-02-20
NO980420D0 (en) 1998-01-30
WO1997005870A2 (en) 1997-02-20
WO1997005870A3 (en) 1997-04-17
AU713031B2 (en) 1999-11-18
AR003176A1 (en) 1998-07-08
KR19990036137A (en) 1999-05-25
BR9609920A (en) 1999-07-06
SK14298A3 (en) 1998-09-09
CZ30598A3 (en) 1998-06-17
HUP9903506A3 (en) 2000-07-28
AU6683496A (en) 1997-03-05
EP0841914A2 (en) 1998-05-20
PL324905A1 (en) 1998-06-22
TR199800244T2 (en) 1998-09-21
MX9800945A (en) 1998-04-30
HUP9903506A2 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
NO980420L (en) Use of griseofulvin to inhibit cancer growth
NO974694L (en) Pharmaceutical preparation containing N-phosphonoglycine derivatives to inhibit cancer and virus growth
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
NO953967L (en) Indole derivatives such as 5-HT1A and / or 5-HT2 ligands
PT1161248E (en) Pharmaceutical composition containing nitrate source and an acidifying agent for treating open wound and burns
ATE103813T1 (en) TOPICAL METRONIDAZOLE FORMULATIONS AND THEIR USE AS MEDICATIONS.
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
AU4385399A (en) Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
NO975662L (en) Use of 1,2,4-triazole derivatives for the preparation of a drug for the treatment of cancer
EP0705098A4 (en) Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
NO980473L (en) Use of fluconazole to inhibit cancer growth
NO953763L (en) Heterocycle-containing amidine derivatives, their preparation and use
NO980419L (en) Use of 1H, 2,4-triazole derivatives to inhibit cancer growth
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
ES2120962T3 (en) ANTIVIRICA COMPOSITION.
TR199903074T2 (en) HMG CoA and farnesyl transfer inhibitors in cancer therapy.
DK0980205T3 (en) Use of a combination of TALL-104 cells with adriamycin or cisplatin in the treatment of malignancies
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
CA2081911A1 (en) Method and composition for treating psoriasis
WO1992013532A3 (en) Naphthoquinone derivatives for the treatment of chronic inflammation
NO20012569L (en) Use of aryl-substituted cyclobutylalkylamines for the treatment of urinary incontinence
BR0009289A (en) Use of vasopeptidase inhibitors to treat angina pectoris
NO20020751L (en) Chemically stabilized chlorite solutions for the treatment of cancer and other diseases
ATE257393T1 (en) KHELLIN PREPARATION AND ITS USE FOR TOPICAL THERAPY

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application